Introduction

Mepolizumab is a monoclonal antibody mostly used in patients with severe eosinophilic asthma.

Aim

To describe the efficacy and safety of Mepolizumab in severe eosinophilic asthma in real life after 5 years treatment in a Centre for care of Severe Astma.

Methods and Materials

We analysed the primary endpoint of rate of decline in FEV1 in patients before and after using Mepolizumab from January 2018 to december 2022. Patients? clinical features have been registered, as well as tolerability to Mepolizumab and respiratory function test in a cohort of patients with severe eosinophilic asthma.

Results

59 patients with severe eosinophilic asthma have been enrolled, 20 males and 39 females, mean 60 yo (range 21-82 y) with severe eosinophilic asthma, identified according to the most recent guidelines. The results have showed a statistically significance about the improvement of FEV1?s value before the Mepolizumab treatment and the FEV1?s value after 5 years, with a p-value of 0.0005. The mean of ? (delta) pre-mepolizumab and ? post-mepolizumab equals 14,35; the 95% confidence interval of this difference ranges from 6.48 to 22.22, standard error was calculated with value of 3.937. It also has been recorded a reduction of the frequency of exacerbations from 3-5 events/y pre-treatment to 1-2 events/y post-treatment and the OCS? dosage from an average of 41,4 mg/d to an average of 29,2 mg/y. No adverse reactions has been recorded during the treatment with Mepolizumab. r code

Conclusions

Mepolizumab improves respiratory function, reduces the frequency of the exacerbations and the OCS? use in patients with severe asthma ipereosinophilic.